Searched for
DRUG DISCOVERY IN INDIA
Wockhardt seeks 14-year data shield for India-made drugsMumbai-based Wockhardt has struck success in its innovative research on a range of antibiotic drugs, bridging a global pipeline gap for dif...- Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
- QClairvoyance's quantum chemistry bet: Transitioning from research to pharma partnershipsQClairvoyance Quantum Labs has performed chemically precise simulations of eight small molecules on an actual quantum computer, marking pro...
- AI halves drug discovery times, but =trial bottleneck remains a costly realityNovo Nordisk, Sanofi and Dr Reddy’s Laboratories are among the companies exploring applications ranging from drug discovery to laboratory a...
- Jubilant Pharmova eyes $150 million through rupee debt sale, bankers sayJubilant Pharmova plans to raise around Rs 14 billion ($150 million) through a three-year rupee bond offering to fund capital expenditure a...
- Europe’s last penicillin plant faces a bitter fight against China’s cheaper drugsThe Sandoz penicillin plant in Kundl, Austria, is under threat from cheaper Chinese antibiotic production. European healthcare programs ben...
- Ministry of Science signs MoU with Peptris for collab in AI-based drug discovery and developmentThe Ministry of Science has entered into a partnership with Peptris Technologies to bolster drug development under the initiative called VI...
- Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-ShawBiocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push f...
- Our central mission must be patient-centric innovation: JP NaddaJ P Nadda urges industry to take discoveries ‘from bench to bedside’ as the FICCI–Lilly Bharat Life Sciences Award backs its inaugural coho...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- ETtech Q&A: From Anthropic to OpenRouter, Menlo Ventures' Matt Murphy and Venky Ganesan on how the firm bets on AIPartners Matt Murphy and Venky Ganesan on the Anthropic bet, life beyond it, where the firm is putting its money now, and why India's AI fu...
- India has biotech talent and know-how, but funding ecosystem lags: Lilly CEOEli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and...
- ‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEOEli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...
- Rasayan Labs launches AI-native drug discovery platform at ICT MumbaiIn an exciting development, Rasayan Labs has unveiled a groundbreaking AI-based platform to enhance computational chemistry and drug discov...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhat is needed in the markets these days is realism. Not fear or gloom, but a clear-eyed acceptance of where things actually stand. Realism...
- Models ready but data isn’t: Google’s Andi Gutmans on AI’s next big hurdleAs companies increasingly deploy AI, Google emphasises the importance of preparing corporate data for effective use. Andi Gutmans stated th...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsThere are times when a watchlist is more important than a buy list. But if you still insist on putting money in the market, look at fundame...
- Zydus Lifesciences expects decent growth for five years as innovation matures: Sharvil PatelZydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to f...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacityAragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-mol...
Load More
